UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN

Leukemia, 2020-04, Vol.34 (4), p.1197-1201

2020

Volltextzugriff (PDF)

Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor

Proceedings of the National Academy of Sciences - PNAS, 2016-10, Vol.113 (41), p.E6145-E6152

2016

Volltextzugriff (PDF)

Defining the transcriptional and cellular landscape of type 1 diabetes in the NOD mouse

PloS one, 2013-03, Vol.8 (3), p.e59701-e59701

2013

Volltextzugriff (PDF)

Protein-RNA interface residue prediction using machine learning: an assessment of the state of the art

BMC bioinformatics, 2012-05, Vol.13 (1), p.89-89, Article 89

2012

Volltextzugriff (PDF)

S1143 The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn’s Disease: Phase 2a APOLLO-CD Study Results

The American journal of gastroenterology, 2023-10, Vol.118 (10S), p.S875-S876

2023

Volltextzugriff (PDF)

Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma

Cells (Basel, Switzerland), 2020-01, Vol.9 (2), p.287

2020

Volltextzugriff (PDF)

Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation

Nature communications, 2024-08, Vol.15 (1), p.6790-19, Article 6790

2024

Volltextzugriff (PDF)

Genome-wide siRNA screen for mediators of NF-κB activation

Proceedings of the National Academy of Sciences - PNAS, 2012-02, Vol.109 (7), p.2467-2472

2012

Volltextzugriff (PDF)

Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways

Frontiers in genetics, 2022-02, Vol.13, p.831779-831779

2022

Volltextzugriff (PDF)

Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathways

BMC medical genomics, 2021-12, Vol.14 (1), p.295-295, Article 295

2021

Volltextzugriff (PDF)

Comparing the biological impact of glatiramer acetate with the biological impact of a generic

PloS one, 2014-01, Vol.9 (1), p.e83757

2014

Volltextzugriff (PDF)

A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis

Genome medicine, 2017-05, Vol.9 (1), p.50-50, Article 50

2017

Volltextzugriff (PDF)

733 Integrative molecular profiling of high-grade primary prostate cancer identifies patients with a biomarker profile that favors the combination of standard of care (SOC) therapy with immunotherapy

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A438-A439

2020

Volltextzugriff (PDF)

B-cell Ligand Processing Pathways Detected by Large-scale Comparative Analysis

Genomics, proteomics & bioinformatics, 2012-06, Vol.10 (3), p.142-152

2012

Volltextzugriff (PDF)

Short paths in protein structure space originate in graph structure

Proceedings of the National Academy of Sciences - PNAS, 2009-12, Vol.106 (51), p.E137-E137; author reply E138

2009

Volltextzugriff (PDF)

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

Blood, 2021-01, Vol.137 (2), p.232-237

2021

Volltextzugriff (PDF)

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM

Blood, 2023-03, Vol.141 (13), p.1574-1583

2023

Volltextzugriff (PDF)

Location of the t(4;14) Translocation Breakpoint Identifies a Subset of Newly-Diagnosed Multiple Myeloma Patients with Poor Prognosis

Blood, 2021-11, Vol.138 (Supplement 1), p.2681-2681

2021

Volltextzugriff (PDF)

High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma

Blood, 2019-03, Vol.133 (11), p.1217-1221

2019

Volltextzugriff (PDF)

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma

Blood, 2023-02, Vol.141 (6), p.620-633

2023

Volltextzugriff (PDF)

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma

Blood, 2022-10, Vol.140 (16), p.1816-1821

2022

Volltextzugriff (PDF)

Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL

Clinical cancer research, 2022-08, Vol.28 (15), p.3367-3377

2022

Volltextzugriff (PDF)

1 – 25 von 88

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(78)

Publikationsform

Sprache

Englisch
(88)

Erscheinungsjahr

n.n

Thema

Science & Technology
(39)
Life Sciences & Biomedicine
(28)
Humans
(25)
Gene Expression
(14)
Hematology
(11)
Animals
(8)
Biochemistry & Molecular Biology
(8)
Female
(8)
Genomes
(8)
Mice
(8)
Multidisciplinary Sciences
(8)
Science & Technology - Other Topics
(8)
Biochemical Research Methods
(7)
Multiple Myeloma - Genetics
(7)
Bioinformatics
(6)
Computer Science
(6)
Genes
(6)
Genomics
(6)
Lymphoid Neoplasia
(6)
Mathematical & Computational Biology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease

Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor

Defining the transcriptional and cellular landscape of type 1 diabetes in the NOD mouse

Protein-RNA interface residue prediction using machine learning: an assessment of the state of the art

S1143 The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn’s Disease: Phase 2a APOLLO-CD Study Results

Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma

Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation

Genome-wide siRNA screen for mediators of NF-κB activation

Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways

Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathways

Comparing the biological impact of glatiramer acetate with the biological impact of a generic

A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis

733 Integrative molecular profiling of high-grade primary prostate cancer identifies patients with a biomarker profile that favors the combination of standard of care (SOC) therapy with immunotherapy

B-cell Ligand Processing Pathways Detected by Large-scale Comparative Analysis

Short paths in protein structure space originate in graph structure

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Location of the t(4;14) Translocation Breakpoint Identifies a Subset of Newly-Diagnosed Multiple Myeloma Patients with Poor Prognosis

High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma

Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL

Suchergebnisse filtern